PYX Resources: Achieving volume and diversification milestones. Watch the video here.
I’m still a bit miffed as to why it’s not being sold under the CE mark for professional use. Tech transfer is complete so there’s nothing to stop this happening. Initial capacity taken or additional variant data required? Who knows, it would be nice to have an update.
I understand the frustration. The stock price continually erodes and nothing seems to be able to stop it at the moment. I’m extremely surprised that we still haven’t heard anything about Vatic. Pretty sure Abingdon made a statement suggesting commencement of commercial sales in May. This is exactly the type of statement that destroys confidence when timelines pass and there’s no communication.
What I would say is that the FDA are prioritising diagnostic’s which bring something different to the table. Vatic’s test only identifies the infectious and the sample method is favourable. Let’s hope the FDA see the benefit.
Abingdon tweeted “we hope to have a decision before the summer”.
These things don’t go in straight lines but my goodness this is a frustrating stock. I think the lack of confidence is down to funding concerns. Get one of the three big ones over the line, the concerns disappear & we see a proper rise.